SAGE Therapeutics (SAGE) Tops Q1 EPS by 4c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($2.46), $0.04 better than the analyst estimate of ($2.50). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $2.41 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• BIG3 Basketball to go public via Graf Global merger at $290 million